Sympathetic nerve activity in renal transplant patients before and after withdrawal of cyclosporine

Journal of Hypertension

Volumn 24, Issue 5, 2006, Pages 957-964

  Hausberg, Martin ^a,e   Lang, Detlef ^a   Levers, Andrea ^a   Suwelack, Barbara ^a   Kisters, Klaus ^a,b   Tokmak, Faruk ^c   Barenbrock, Michael ^a,d   Kosch, Markus ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b ST ANNA HOSPITAL   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d Dialysis Center   (Germany)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Chronic allograft nephropathy; Cyclosporine; Kidney; Sympathetic nervous system; Transplantation

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NORADRENALIN; PREDNISOLONE;

ADRENERGIC SYSTEM; ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; KIDNEY TRANSPLANTATION; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; SURGICAL PATIENT; SYMPATHETIC NERVE;

EID: 33646377898     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000222767.15100.e4     Document Type: Article

References (32)

1. Kendrick E. Cardiovascular disease and the renal transplant recipient. Am J Kidney Dis 2001; 38 (6 Suppl. 6):S36-S43.
2. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105:1354-1359.
3. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106:1974-1979.
4. European Multicentre Trial Group. Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicentre trial. Lancet 1983; 2:986-989.
5. Jensik SC. Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group. Transplant Proc 1998; 30:1216-1218.
6. Morales JM, Andres A, Rengel M, Rodicio JL. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant 2001; 16 (Suppl. 1):121-124.
7. Sanders CE Jr, Curtis JJ. Role of hypertension in chronic renal allograft dysfunction. Kidney Int Suppl 1995; 52:S43-S47.
8. Schnuelle P, van der Heide JH, Tegzess A, Verburgh CA, Paul LC, van der Woude FJ, de Fijter JW. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 2002; 13:536-543.
9. Lyson T, Ermel LD, Belshaw PJ, Alberg DG, Schreiber SL, Victor RG. Cyclosporine- and FK506-induced sympathetic activation correlates with calcineurin-mediated inhibition of T-cell signaling. Circ Res 1993; 73:596-602.
10. Scherrer U, Vissing SF, Morgan BJ, Rollins JA, Tindall RS, Ring S, et al. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med 1990; 323:693-699.
11. Kaye D, Thompson J, Jennings G, Esler M. Cyclosporine therapy after cardiac transplantation causes hypertension and renal vasoconstriction without sympathetic activation. Circulation 1993; 88:1101-1109.
12. Rundqvist B, Elam M, Eisenhofer G, Friberg P. Normalization of total body and regional sympathetic hyperactivity in heart failure after heart transplantation. J Heart Lung Transplant 1996; 15:516-526.
13. Zhang W, Victor RG. Calcineurin inhibitors cause renal afferent activation in rats: a novel mechanism of cyclosporine-induced hypertension. Am J Hypertens 2000; 13:999-1004.
14. Siggard-Anderson J. Venous occlusion plethysmography on the calf. Dan Med Bull 1970; 17:1-68.
15. Hausberg M, Hoffman RP, Somers VK, Sinkey CA, Mark AL, Anderson EA. Contrasting autonomic and hemodynamic effects of insulin in healthy elderly versus young subjects. Hypertension 1997; 29:700-705.
16. Cockroft DW, Gault HM. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
17. Hausberg M, Mark AL, Winniford MD, Brown RE, Somers VK. Sympathetic and vascular effects of short-term passive smoke exposure in healthy nonsmokers. Circulation 1997; 96:282-287.
18. Floras JS, Legault L, Morali GA, Hara K, Blendis LM. Increased sympathetic outflow in cirrhosis and ascites: direct evidence from intraneural recordings. Ann Intern Med 1991; 114:373-380.
19. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327:1912-1918.
20. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995; 25:878-882.
21. DiBona GF, Jones SY, Kopp UC. Renal mechanoreceptor dysfunction: an intermediate phenotype in spontaneously hypertensive rats. Hypertension 1999; 33:472-475.
22. Katholi RE, Whitlow PL, Hageman GR, Woods WT. Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves in the dog. J Hypertens 1984; 2:349-359.
23. Zhang W, Li JL, Hosaka M, Janz R, Shelton JM, Albright GM, et al. Cyclosporine A-induced hypertension involves synapsin in renal sensory nerve endings. Proc Natl Acad Sci U S A 2000; 97:9765-9770.
24. Hansen JM, Abildgaard U, Fogh-Andersen N, Kanstrup IL, Bratholm P, Plum I, Strandgaard S. The transplanted human kidney does not achieve functional reinnervation. Clin Sci (Lond) 1994; 87:13-20.
25. Koomans HA, Ligtenberg G. Mechanisms and consequences of arterial hypertension after renal transplantation. Transplantation 2001; 72 (6 Suppl.):S9-S12.
26. Textor SC, Canzanello VJ, Taler SJ, Wilson DJ, Schwartz LL, Augustine JE, et al. Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc 1994; 69:1182-1193.
27. Sata M, Walsh K. Cyclosporine downregulates Fas ligand expression on vascular endothelial cells: implication for accelerated vasculopathy by immunosuppressive therapy. Biochem Biophys Res Commun 1999; 263:430-432.
28. Wallin BG, Thompson JM, Jennings GL, Esler MD. Renal noradrenaline spillover correlates with muscle sympathetic activity in humans. J Physiol 1996; 491:881-887.
29. Stein CM, He H, Pincus T, Wood AJ. Cyclosporine impairs vasodilation without increased sympathetic activity in humans. Hypertension 1995; 26:705-710.
30. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003; 14:425-430.
31. Wallin BG, Sundlof G, Stromgren E, Aberg H. Sympathetic outflow to muscles during treatment of hypertension with metoprolol. Hypertension 1984; 6:557-562.
32. Wenzel RR, Allegranza G, Binggeli C, Shaw S, Weidmann P, Luscher TF, Noll G. Differential activation of cardiac and peripheral sympathetic nervous system by nifedipine: role of pharmacokinetics. J Am Coll Cardiol 1997; 29:1607-1614.